Google Spinoff Verily Moves into the COVID-19 Antibody Testing Business

Google Spinoff Verily Moves into the COVID-19 Antibody Testing Business

Verily, a spinoff from Google, is owned by parent company Alphabet and recently launched a research study focusing on how the immune system interacts with SARS-COV-2. Based on the existing Project Baseline initiative, the Silicone Valley-based group will leverage advanced technology applied to longitudinal health care research to help researchers take on the COVID-19 pandemic. As Verily already initiated testing across California, their Baseline Antibody Research focuses on serology tests for those individuals who have already received a nasal swab test from Verily’s testing initiative. The study starts in California and may expand from there.

Verily’s testing efforts will leverage its Project Baseline.

What is Project Baseline?

As TrialSite News has covered, Project Baseline is designed to engage patients and clinicians in research, increase the speed and ease of conducting studies and collect more comprehensive, higher quality data, including outside the four walls of the clinic.

Project Baseline is a broad effort to map human health, led by Verily Life Sciences (formerly Google Life Sciences), Alphabet, Inc’s health sciences division, announced July 24, 2014.


Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee